Massachusetts Financial Services Co. MA Sells 4,331 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Massachusetts Financial Services Co. MA cut its position in MiMedx Group, Inc. (NASDAQ:MDXG) by 2.4% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 178,932 shares of the company’s stock after selling 4,331 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in MiMedx Group were worth $1,057,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Victory Capital Management Inc. raised its holdings in MiMedx Group by 909.0% in the 2nd quarter. Victory Capital Management Inc. now owns 138,449 shares of the company’s stock worth $959,000 after acquiring an additional 124,727 shares during the last quarter. Farther Finance Advisors LLC raised its stake in shares of MiMedx Group by 88.6% in the third quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company’s stock worth $145,000 after purchasing an additional 11,557 shares during the last quarter. Isthmus Partners LLC lifted its holdings in shares of MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after purchasing an additional 91,714 shares in the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after buying an additional 770,744 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in MiMedx Group by 13.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company’s stock worth $254,000 after buying an additional 3,806 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Performance

MDXG opened at $9.43 on Thursday. The company’s 50 day moving average is $6.79 and its 200 day moving average is $6.88. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.39 billion, a price-to-earnings ratio of 17.15 and a beta of 1.94. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $9.64.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on MDXG shares. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 target price on shares of MiMedx Group in a research note on Thursday, August 1st. StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Finally, Craig Hallum decreased their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.